Business
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\n\n \n MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- – Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced its initiation of a first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer. It is anticipated that the first patient will be enrolled in early Q2 2018.  Clinical sites participating in the study are expected to include the University of Florida, in Gainesville, Florida, the Ashford Cancer Centre in Adelaide, the Olivia Newton-John Cancer and Wellness Centre in Melbourne and the Blacktown Cancer and Haematology Centre in Sydney, Australia. The Company further notes that it will require additional capital to complete this study. “We are enthusiastic about this novel class of anti-cancer drugs that were discovered by University of Florida’s Professor Emeritus Raymond Bergeron, Ph.D.,” said Jonathan Licht, M.D., director of the University of Florida Health Cancer Center.  “We're excited to partner with Sun BioPharma to study this new agent in patients with pancreatic cancer who so desperately need new treatment options.” Sun BioPharma anticipates enrollment of patients in the dose-escalation phase during 2018, with safety information, and response rate and progression-free-survival efficacy endpoints to be reported periodically. Sun BioPharma also announced the completion of the first-in-human safety study of SBP-101 in previously treated patients with pancreatic ductal adenocarcinoma (PDA). SBP-101 was well tolerated and signals of efficacy were observed at dose levels below the Maximum Tolerated Dose (MTD). David B. Kaysen, President and CEO of Sun BioPharma, Inc. said, “We are extremely excited about the results of this trial which affirmed our expectations for the safety profile of SBP-101 and, unexpectedly, provided encouraging signals of efficacy in these seriously ill patients.  Our clinical team anticipates presentation of final results of this study at a major oncology conference later this year.” About SBP-101SBP-101 is a first-in-class, proprietary, polyamine compound designed to exert therapeutic effects in a mechanism specific to ...